-oxide synthase inhibitors (10) and antibacterial agents (11) . Furthermore, 5-nitro-substitutedhaloimidazoles, an interesting class of such compounds, showed important biological activity as potential radiosensitizers (12) . Other imidazole derivatives having 5-alkylsulfanyl residues exhibited remarkable antitumor activity (13) . The facile replacement of halogen in these compounds prompted many laboratories (14) (15) (16) to develop a new high-yielding method leading to interesting imidazole compounds bearing various alkylsulfanyl or alkylamino groups via nucleophilic substitution of the halogen by N or S nucleophiles.
Based on these pharmacological activities, and in continuation of our work on 4-nitroimidazoles (17) (18) (19) (20) , we report here the synthesis of new 5-substituted piperazinyl-4--nitroimidazole derivatives and the evaluation of their anti-HIV activity.
EXPERIMENTAL
Melting points are uncorrected and were measured on a Büchi melting point apparatus B-545 (Büchi Labortechnik AG, Switzerland). Microanalytical data were obtained with a Vario, Elemental apparatus (Shimadzu, Japan). NMR spectra were recorded on 300 and 600 MHz ( 1 H) and on 62.9 MHz ( 13 C) spectrometers (Bruker, Germany) with TMS as internal standard and on the d scale in ppm. Heteronuclear assignments were verified by the 1 H-13 C HMBC experiment. Mass spectra were recorded at 70 eV on EI and FAB mass spectra were measured on a MAT 8200 spectrometer (Finnigana MAT, USA) using 3-nitrobenzyl alcohol (NBOH) or glycerol as matrices. Some molecular ions were detected by doping the sample with Na + ion.
Physico-chemical and spectral data for the synthesized compounds are given in Tables I and II. Synthetic routes are presented in Schemes 1-3.
Syntheses 1-[4-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl]-2-chloromethylene ketone (2)
To a solution of 1 (20) (315 mg, 1.0 mmol) in CH 2 Cl 2 (15 mL) containing triethylamine (110 mg, 1.0 mmol), 2-chloroacetyl chloride (112 mg, 1.0 mmol) was added and stirred at room temperature for 3 h. The solution was evaporated to dryness and the residue was recrystallized from EtOH to give 2. 
2-Alkylthio-1-[4-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl]ethanone (3-9)
A solution of 2 (390 mg, 1.0 mmol) in CH 2 Cl 2 (20 mL) containing triethylamine (0.10 g, 1.0 mmol) was treated with alkylthiols (1.0 mmol) and the mixture was stirred at 80-90°C for 4 h. After cooling, the mixture was evaporated to dryness and the residue was recrystallized from EtOH to give the desired ketones. 1-[4-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl]-2-(benzylthio)ethanone (6), 1-[4-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl]-2-(4-chlorobenzylthio)-ethanone (7), 1-[4-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl]-2-(napthalenthio)-ethanone (8), and ethyl 2-[2-(4-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)piperazin-1-yl)-2 oxoethylthio]acetate (9) were prepared from sodium thiophenolate (132 mg), 4-chlorobenzenethiol (144 mg), 4-methoxybenzenethiol (140 mg), benzylthiol (124 mg), 4-chlorobenzylthiol (158 mg), sodium naphthylthiol (160 mg), and ethyl 3-mercaptopropanoate (134 mg), respectively.
1-[4-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl]-2-(phenylthio)ethanone (3), 1-[4-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl]-2-(4-chlorophenylthio)ethanone (4), 1-[4-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl]-2-(4-methoxyphenylthio) ethanone (5),

1-[4-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl]-2-(naphthalene-1-ylsulphonyl) ethanone (10)
A solution of 8 (200 mg, 0.39 mmol) in CH 2 Cl 2 (10 mL) was stirred with m-chloroperbenzoic acid (mCPBA) (470 mg, 2.15 mmol) for 6 h at room temperature; it was partitioned with water (10 mL) and the organic layer was dried (Na 2 SO 4 ), filtered and evaporated to dryness. The residue was recrystallized from EtOH to give 10.
General synthesis of alkyl-[4-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl)ketones (11-18, 20)
To a solution of 1 (0.32 g, 1.0 mmol) in CH 2 Cl 2 (20 mL) containing triethylamine (0.10 g, 1.0 mmol), alkyl carbonyl chloride (1.0 mmol) was added and stirred at room temperature. A few drops of water were added and the solution was stirred for 1 h, then partitioned between CHCl 3 (3 x 20 mL) and water (20 mL). The combined organic layer was dried (Na 2 SO 4 ), filtered and evaporated to dryness. The residue was recrystallized from EtOH to give the desired ketone derivative.
[ (20) were prepared from acetyl chloride (79 mg), 4-chlorobenzoyl chloride (175 mg), 4-fluorobenzoyl chloride (158 mg), 4-nitrobenzoyl chloride (185 mg), 4-methoxybenzoyl chloride (171 mg), 2,4-dichlorobenzoyl chloride (210 mg), thiophene-2-carbonyl chloride (147 mg), methyl 3-(chlorocarbonyl)propanoate (151 mg), and 9H-carbazyl-9-yl)methyl chloroformate (260 mg), respectively.
4-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl]methyl ketone (11), [4-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl](4-chlorophenyl)ketone (12), [4-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl](4-fluorophenyl)ketone (13), [4-(1-benzyl-2-ethyl--4-nitro-1H-imidazol-5-yl)-piperazin-1-yl](4-nitrophenyl)ketone (14), [4-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl](4-methoxyphenyl)ketone (15), [4-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl](2,4-dichlorophenyl)ketone (16), [4-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl](thiophen-2-yl)ketone (17), methyl 4-[4-(1-benzyl-2-ethyl -4-nitro-1H-imidazol-5-yl)-piperazin-1-yl]-4-oxo-butanoate (18), and [4-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl](9H-carbazol-9-yl)methyl carboxylate
4-[4-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl]-4-oxo-butanamide (19)
A solution of 18 (208 mg, 0.48 mmol) in NH 3 /MeOH solution (10 mL) was stirred at 23°C for 16 h. The solution was evaporated to dryness and the residue was purified on a short column of silica gel (5 g). Elution with CHCl 3 -MeOH (9:1) afforded pure 19. Indol-3-yl)-1-[4-(1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)-piperazin-1-yl] propan-1-one (22) To a cold solution of 1 (630 mg, 2.0 mmol), at -5°C, in MeCN (10 mL), 3-(1H-indol--3-yl)propanoic acid (21) (378 mg, 2.0 mmol), hydroxybenzotriazole (HOBt) (270 mg, 2.0 mmol) and N,N'-dicyclohexyl-carbodiimide (DCC) (413 mg, 2.0 mmol) were added successively. The reaction mixture was stirred at 0°C for 1 h, at 5°C for 1 h, and at 23°C for 16 h. Dicyclohexylurea (DCU) was filtered and the filtrate was evaporated to dryness. The residue was stirred with ethyl acetate, filtered, washed successively with saturated NaCl solution, 5% NaHCO 3 solution, 1.0 mol L -1 HCl, and finally with water. The organic layer was dried (Na 2 SO 4 ), filtered and evaporated to dryness to give 22.
3-(1H-
Cytotoxicity and in vitro anti-HIV assays
Compounds 2-20 and 22 were tested for their in vitro anti-HIV-1 (strain III B ) and HIV-2 (strain ROD) activity in human T-lymphocyte (MT-4) cells using the MT-4/MTT assay (21) . The results are summarized in Table III , in which the data for efavirenz (22) and capravirine (6) were included for comparison.
All cytotoxicity and anti-HIV activity assays were performed in 96-well microtiter plates (Falcon 3072; Becton Dickinson, USA). Determination of cytotoxicity involved plating of 4 × 10 4 CEM cells (100 mL) into each well in the presence of a given amount of the test compound (100 mL). The cells were allowed to proliferate for 96 h at 37°C in a humidified atmosphere in which the CO 2 concentration was controlled. At the end of the incubation period, the cells were counted in a Coulter counter (model ZB; Coulter Electronics Ltd., UK). The 50% cytotoxic concentration (mg mL -1 ) (CC 50 ) was defined as the concentration of compound that inhibited CEM cell proliferation by 50%. The procedures used to assess the anti-HIV activity in cell culture were based on assessment of the inhibition of HIV-induced giant cell formation in CEM cell cultures at day 4 postinfection by microscopic examination. Briefly, CEM cells were suspended at 250,000 cells mL -1 in culture medium and infected with HIV at approximately 100 times the 50% cell culture infectious dose (CCID 50 ) per mL. Then, 100 mL of the infected cell suspension was added to 200-mL microtiter plate wells containing 100 mL of an appropriate dilution of the test compound. After 4 days of incubation at 37°C, the cell cultures were examined for syncytium formation. The 50% effective concentration (EC 50 , mg mL -1 ) was defined as the compound concentration required to inhibit virus-induced syncytium formation by 50%. The selectivity index SI is defined as CC 50 /EC 50 .
RESULTS AND DISCUSSION
Various 5-alkylamino and 5-alkylsulfanyl derivatives of imidazole derivatives (17, 18) have been prepared recently in our laboratory via nucleophilic displacements of the bromine group activated by an adjacent nitro group. Our efforts are continued in preparation of such compounds bearing piperazines substituted by alkylsulfanyl and amido groups to furnish potentially active analogues. 1-(Benzyl-2-ethyl-4-nitro-1H-imidazole--5-yl)piperazine 1 has been selected for the synthesis of our target, amide molecules, by treatment with different acyl chlorides. Thus, treatment of 1 with 2-chloroacetyl chloride in the presence of triethylamine at room temperature afforded 2 (50%).
Treatment of 2 with alkylthiols: sodium thiophenolate, 4-chlorobenzenethiol, 4-methoxybenzenethiol, benzylthiol, 4-chlorobenzylthiol, sodium naphthylthiol, ethyl 3-mercaptopropanoate at 80-90°C in the presence of triethylamine gave compounds 3-9 (58-72%). Oxidation of 8 with mCPBA in the presence of a base furnished, after purification, the sulphone 10 (76%) (Scheme 1).
Structures of the newly synthesized compounds 2-9 were assigned by the 1 H, 13 C NMR and mass spectra. The 1 H NMR spectra showed rather similar patterns for the phenyl and ethyl protons, while the singlets in the region d 5.17-5.12 ppm were attributed to methylene of the benzyl group. Resonances of the piperazine moiety appeared Further, other models of imidazole derivatives bearing keto substituted piperazine residues were prepared. Thus, treatment of 1 with alkyl carbonyl chlorides: acetyl chloride, 4-chlorobenzoyl chloride, 4-fluorobenzoyl chloride, 4-nitrobenzoyl chloride, 4-methoxybenzoyl chloride, 2,4-dichlorobenzoyl chloride, thiophene-2-carbonyl chloride, methyl 3-(chlorocarbonyl)propanoate, and (9H-carbazyl-9-yl)methyl chloroformate in the presence of triethylamine at room temperature afforded 11-20 in 40-81% yield. The amide 19 was prepared (91%) from treatment of 18 with NH 3 /MeOH at room temperature (Scheme 2).
The assignment of protons and carbons of the imidazole ring was deduced from comparison with compounds 11-19 and our previously reported data on nitroimidazoles (17) .
A suitable coupling method (23) was employed for the formation of amide by reaction of the carboxylic acid group with amine, using 1-hydroxybenzotriazole (HOBt) (24, 25) and N,N'-dicyclohexylcarbodiimide (DCC) (26) as coupling reagents. Therefore, our work was modified by selecting the 3-(1H-indol-3-yl)propanoic acid 21 as a precursor for the synthesis of new derivatives to examine the antiviral activity by Reverse transcriptase (RT) is a key enzyme, which plays an essential and multifunctional role in the replication of HIV-1 and thus is considered to be an attractive target for inhibition of HIV-1 replication (27) . Non-nucleosides reverse transcriptase inhibitors (NNRTIs), a group of structurally diverse compounds, have been reported to directly inhibit the enzyme in an allosteric fashion by binding to a pocket near the polymerase active site (28) . To date, many classes of NNRTIs have been identified, e.g. capravirine and efavirenz have been approved for the treatment of HIV-1 infection. However, NNRTI-containing regimens are compromised by rapid emergence of drug-resistant strains carrying the amino acid mutations surrounding the NNRTI binding pocket.
Our target was the synthesis of new 4-nitroimidazoles, leading to inhibition of HIV by inhibition of RT and reduction of the drug-resistance strains. Compounds 2 and 9 were found to be most active among the tested compounds inhibiting HIV replication in cell culture. Compound 2 showed inhibition of HIV-1 with an effective concentration (EC 50 ) of 0.45 mg mL -1 and HIV-2 with EC 50 of 0.50 mg mL -1 , while compound 9 showed inhibition of HIV-2 with EC 50 of 2.48 and a CC 50 of 10.67 ± 0.19 mg mL -1 , resulting in a selectivity index of 4.
Based on the chemical structure and the fact that compound 9 inhibits HIV-1, but not HIV-2, replication, this molecule can be proposed to act as an non-nucleoside reverse transcriptase inhibitor (NNRTI).
In our study 4-nitroimidazoles, we have explored the SARs of substituents in a series of 4-nitroimidazoles (parts II-IV) in order to identifity novel NNTRIs capable of inhibiting both HIV-1 and HIV-2 replication. The docking study suggested the importance of a piperazine group on the imidazole ring substituted by aliphatic carbonyl groups such as COCH 2 Cl, CO(CH 2 ) n R or sulphonamides for potent inhibitory activity against RT. 
CONCLUSIONS
The anti-HIV activity of compound 9 was assessed against an NNRTI-resistant strain (RT K103N and Y181C) revealing a total loss of the inhibitory activity on HIV replication, confirming the typical first generation NNRTI mode of action of this compound. The structure-activity relationships (SARs) of 4-nitroimidazole derivatives have suggested the importance of a piperazine group on the imidazole ring substituted by aliphatic carbonyl groups such as COCH 2 Cl, CO(CH 2 ) n R or sulphonamides for potent inhibitory activity against RT. This could lead to the discovery of more potent and selective analogues that will allow the elucidation of their molecular mode of action.
